On April 10, 2019 Eli Lilly and Company (NYSE: LLY) reported that it will announce its first-quarter 2019 financial results on Tuesday, April 30, 2019 (Press release, Eli Lilly, APR 10, 2019, View Source [SID1234535110]). Lilly will also conduct a conference call on that day with the investment community and media to further detail the company’s financial performance.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The conference call will begin at 9 a.m. Eastern time. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly’s website at View Source A replay will also be available on the website following the conference call.

On April 10, 2019 I-Mab Biopharma ("I-Mab"), a clinical stage biopharmaceutical company exclusively focused on the development of potential first-in-class and best-in-class biologics in immuno-oncology and autoimmune diseases reported that it has enters into a collaboration with Roche for I-Mab’s clinical study to evaluate TJD5 in combination with atezolizumab (TECENTRIQ) (Press release, I-Mab Biopharma, APR 10, 2019, View Source [SID1234535096]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Roche will supply atezolizumab (TECENTRIQ) to I-Mab for use in clinical study in combination with TJD5. All rights generated in the study will belong jointly to I-Mab and Roche.

TJD5 is a proprietary innovative CD73 antibody from I-Mab’s discovery pipeline with best-in-class potential. CD73 is an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine, which contributes to a highly immunosuppressive tumor micro-environment. On January 18, 2019, TJD5 received IND clearance from the U.S. FDA.

Dr. Joan Shen, Head of R&D of I-Mab, commented, "We are thrilled to collaborate with Roche, a global leader of cancer immunotherapy, and we look forward to maximizing the potential of TJD5 to meet the clinical needs all over the world."

About TJD5:
TJD5 is a differentiated monoclonal antibody against another promising immuno-oncology target, CD73. It is expected to stimulate the immuno-suppressive tumor micro-environment and to work in concert with other cancer therapies such as PD-1 and PD-L1 antibodies. TJD5 acts through a unique intra-dimerization mechanism for anti-cancer activities and inhibit the target enzyme activity completely. This unique mechanism of action ensures the molecule to work normally without a "hook effect" as evident in our preclinical studies.

On April 10, 2019 McKesson Corporation (NYSE:MCK) reported that it will release financial results for its fourth quarter ended March 31, 2019 on Wednesday, May 8, 2019, prior to the opening of trading on the New York Stock Exchange (Press release, McKesson, APR 10, 2019, View Source [SID1234535095]). The company has scheduled a conference call for 8:00 AM Eastern Time (5:00 AM Pacific Time), during which Brian Tyler, chief executive officer, and Britt Vitalone, executive vice president and chief financial officer, will review these results.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The dial-in number for individuals wishing to participate on the call is 323-794-2093. Holly Weiss, senior vice president, Investor Relations is the leader of the call and the password is ‘McKesson’.

Additionally, Brian Tyler and Britt Vitalone will be participating in the Bank of America Merrill Lynch Health Care Conference on Tuesday, May 14, 2019, in Las Vegas, NV.

Audio webcasts will be available live and archived for both events on the company’s Investor Relations website at View Source A complete listing of upcoming events for the investment community is available on the company’s Investor Relations website.

On April 10, 2019 Cullgen Inc. (Cullgen), a biotechnology company dedicated to the development of targeted protein degraders for the treatment of diseases lacking effective therapeutic approaches, reported it has received a $16 million Series A financing from two prominent international venture capital firms, Sequoia Capital China (Sequoia) and Highlight Capital (HC) (Press release, Cullgen, APR 10, 2019, View Source [SID1234535094]). The financing will support the development of Cullgen’s internal pipeline of targeted protein degraders in oncology and other diseases, as well as the company’s efforts to discover novel E3 ligands that may be used as part of a targeted protein degrader complex. Sequoia will also assign a board member to join the Cullgen board.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are delighted to have the support of Sequoia and HC", said Dr. Ying Luo, Chairman and President of Cullgen "Since our founding in early 2018 we have made significant advancement of our targeted protein degradation platform which has directly led to the identification of several pre-clinical assets that we are rapidly advancing towards the clinic. In addition to these core scientific advancements, over the past year the company has assembled a distinguished board of scientific advisors, put in place an outstanding senior management team, and established a state-of-the-art laboratory facility that is run by more than 40 highly talented employees. We are grateful that Sequoia and HC will be part of Cullgen’s mission to develop novel targeted protein degraders for the treatment of debilitating diseases."

On April 10, 2019 Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, reported that a late-breaking abstract detailing results from the Company’s recently completed multicenter Phase II trial in patients with advanced liver cancer has been accepted for oral presentation at the late-breaking abstract session of the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) (Press release, Can-Fite BioPharma, APR 10, 2019, View Source [SID1234535093]). The world’s largest clinical cancer research meeting, ASCO (Free ASCO Whitepaper), will take place from May 31 to June 4, 2019 in Chicago, Illinois.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The abstract titled: "A phase II, randomized, double-blind, placebo-controlled trial evaluating efficacy and safety of namodenoson (CF102), an a3 adenosine receptor agonist (A3AR), as a second-line treatment in patients with Child-Pugh B (CPB) advanced hepatocellular carcinoma (HCC)", will be presented in an oral session by Prof. Salomon Stemmer, Principal Investigator of the Phase II trial.

Oral Abstract Presentation Details
Date: Tuesday, June 02, 2019
Time: 8:00 am CDT
Oral abstract session: Developmental Immunotherapy and Tumor Immunobiology

"We consider ASCO (Free ASCO Whitepaper)’s acceptance of our late breaking oral presentation a testament to the compelling data coming out of our recently completed Phase II study of Namodenoson. We believe this reflects the oncology community’s assessment that our Phase II Namodenoson trial is a high-impact study with significant relevance in the treatment of liver cancer," stated Can-Fite CEO Pnina Fishman.

Can-Fite is currently designing and planning the protocol for a Phase III study with the support of the world’s leading oncologists and regulatory experts including Dr. Josep Llovet, Founder and Director of the Liver Cancer Program and Full Professor of Medicine at the Mount Sinai School of Medicine, New York, a key opinion leader who will serve as the Phase III study’s Principal Investigator.

About Namodenoson

Namodenoson is a small orally bioavailable drug that binds with high affinity and selectivity to the A3 adenosine receptor (A3AR). Namodenoson is being evaluated as a second line treatment for hepatocellular carcinoma, with a recently completed Phase II trial and planned Phase III trial in this indication. The drug is currently in an ongoing Phase II trial as a treatment for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). A3AR is highly expressed in diseased cells whereas low expression is found in normal cells. This differential effect accounts for the excellent safety profile of the drug.